Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1432031 | 1.00 | PPM1B (0.34) | PPM1BPTPN1PPP1CCMAPTL3MBTL1 | |
| SCHEMBL679530 | 0.70 | MAPT (0.35) | PPM1BPTPN1PPP1CCMAPTL3MBTL1 | |
| SCHEMBL679529 | 0.70 | MAPT (0.35) | PPM1BPTPN1PPP1CCMAPTL3MBTL1 | |
| SCHEMBL4925534 | 0.70 | MAPT (0.35) | PPM1BPTPN1PPP1CCMAPTL3MBTL1 | |
| SCHEMBL679446 | 0.68 | MAPT (0.33) | PPM1BPTPN1MAPTL3MBTL1MEN1 | |
| SCHEMBL684824 | 0.68 | MAPT (0.33) | PPM1BPTPN1MAPTL3MBTL1MEN1 | |
| SCHEMBL21674388 | 0.64 | MAOA (0.40) | MEN1KMT2AALDH1A1KDM4EHPGD | |
| SCHEMBL31296900 | 0.63 | LMNA (0.50) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL20924927 | 0.61 | NPSR1 (0.36) | MAPTL3MBTL1ALDH1A1HPGDGAA | |
| Alcohol SCHEMBL3398638 | 0.60 | ALDH1A1 (0.56) | MAPTMEN1KMT2AALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923465-B2 | CB2 agonists; pain, neurodegenative disorders, eating disorders, weight loss or control, obesity, dyslipidemia, drug abuse, vision defect, neurodegenerative diseases; 5-(2,4-difluorophenyl)-4,5-diazatricyclo[5.2.1.0.sup.2,6.]deca-2-(6),3-dien-3-yl-phenylmethanone; antiinflammatory agent, antidepressant | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-04-12 | — | — | US | claimed |
| EP-1902034-B1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS SA (CH) | 2011-03-30 | — | — | EP | claimed |
| US-20080234259-A1 | Novel Cannabinoid Receptor Ligands, Pharmaceutical Compositions Containing Them, and Process For Their Preparation | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-09-25 | — | — | US | claimed |
| US-8420689-B2 | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-04-16 | — | — | US | disclosed |
| US-20120142748-A1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-06-07 | — | — | US | disclosed |
| US-7923465-B2 | CB2 agonists; pain, neurodegenative disorders, eating disorders, weight loss or control, obesity, dyslipidemia, drug abuse, vision defect, neurodegenerative diseases; 5-(2,4-difluorophenyl)-4,5-diazatricyclo[5.2.1.0.sup.2,6.]deca-2-(6),3-dien-3-yl-phenylmethanone; antiinflammatory agent, antidepressant | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-04-12 | — | — | US | disclosed |
| EP-1902034-B1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS SA (CH) | 2011-03-30 | — | — | EP | disclosed |
| US-20080234259-A1 | Novel Cannabinoid Receptor Ligands, Pharmaceutical Compositions Containing Them, and Process For Their Preparation | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-09-25 | — | — | US | disclosed |
| EP-1902034-A1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | Glenmark Pharmaceuticals S.A. (CH) | 2008-03-26 | — | — | EP | disclosed |
| WO-2006129178-A1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS S.A. (US) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142748-A1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | CNR1, CNR2, GPR18 | PPM1B 2313/4885PTPN1 1615/4885PPP1CC 2508/4885 |
| US-20080234259-A1 | Novel Cannabinoid Receptor Ligands, Pharmaceutical Compositions Containing Them, and Process For Their Preparation | CNR2, CNR1, OPRL1 | PPM1B 1352/4885PTPN1 2078/4885PPP1CC 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.